slides · global inventory
Resolution
Beat collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 42,534
Current window 28,411-28,440
Pages 1,418
Rows per page 30
Beat
28,411-28,440 of 42,534
38
AstraZeneca | Investor Event Presentation Deck | 42 slidesAstraZeneca | Investor Event Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
39
AstraZeneca | Investor Event Presentation Deck | 42 slidesAstraZeneca | Investor Event Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
40
AstraZeneca | Investor Event Presentation Deck | 42 slidesAstraZeneca | Investor Event Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
41
Clinical trial baseline characteristics table.AstraZeneca | Investor Event Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
42
AstraZeneca | Investor Event Presentation Deck | 42 slidesAstraZeneca | Investor Event Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
20
Goldman Sachs | Investment Banking Pitch Book | 52 slidesGoldman Sachs | Investment Banking Pitch Book | 52 slides · Goldman Sachs
Consulting deck Investment bank Beat · Impact & Next Steps1 hit
21
Uses a football field chart visualization to compare valuation ranges against current share price and offer price.Goldman Sachs | Investment Banking Pitch Book | 52 slides · Goldman Sachs
Consulting deck Investment bank Beat · Impact & Next Steps1 hit
22
The slide uses a bar-chart-in-table format to visualize valuation ranges. It includes a legend for 'Current' vs '23-Nov-2022' data.Goldman Sachs | Investment Banking Pitch Book | 52 slides · Goldman Sachs
Consulting deck Investment bank Beat · Impact & Next Steps1 hit
23
Includes base case and tax adjustment impact tables.Goldman Sachs | Investment Banking Pitch Book | 52 slides · Goldman Sachs
Consulting deck Investment bank Beat · Impact & Next Steps1 hit
24
Includes Goldman Sachs branding and confidential watermark.Goldman Sachs | Investment Banking Pitch Book | 52 slides · Goldman Sachs
Consulting deck Investment bank Beat · Impact & Next Steps1 hit
25
Includes sensitivity analysis on NTM P/E multiples (8.0x, 9.0x, 10.0x) and comparison against CD&R offer and current share price.Goldman Sachs | Investment Banking Pitch Book | 52 slides · Goldman Sachs
Consulting deck Investment bank Beat · Impact & Next Steps1 hit
26
Includes a bar chart showing annual median premia (1-day, 30-day, 52-week high) and a table calculating implied share prices based on these historical benchmarks.Goldman Sachs | Investment Banking Pitch Book | 52 slides · Goldman Sachs
Consulting deck Investment bank Beat · Impact & Next Steps1 hit
27
Includes a comparison table of historical percentiles and a bar chart showing annual median premia from 2018-2022 alongside the CD&R offer.Goldman Sachs | Investment Banking Pitch Book | 52 slides · Goldman Sachs
Consulting deck Investment bank Beat · Impact & Next Steps1 hit
28
Includes a highlighted column for the 'Original & Current Offer' at $50.00 per share.Goldman Sachs | Investment Banking Pitch Book | 52 slides · Goldman Sachs
Consulting deck Investment bank Beat · Impact & Next Steps1 hit
29
Goldman Sachs | Investment Banking Pitch Book | 52 slidesGoldman Sachs | Investment Banking Pitch Book | 52 slides · Goldman Sachs
Consulting deck Investment bank Beat · Impact & Next Steps1 hit
30
Includes Goldman Sachs branding and Investment Banking Division header.Goldman Sachs | Investment Banking Pitch Book | 52 slides · Goldman Sachs
Consulting deck Investment bank Beat · Impact & Next StepsLoop · Cost Of Inaction1 hit
31
The slide highlights a 'Consolidation Sweet Spot' for firms with $300mm-$3000mm AUM.Goldman Sachs | Investment Banking Pitch Book | 52 slides · Goldman Sachs
Consulting deck Investment bank Beat · Impact & Next StepsLoop · Cost Of Inaction1 hit
32
Includes a list of top 2021 RIA acquirers and a callout for Q3 2022 transaction leaders.Goldman Sachs | Investment Banking Pitch Book | 52 slides · Goldman Sachs
Consulting deck Investment bank Beat · Impact & Next StepsLoop · Cost Of Inaction1 hit
33
The slide uses a Venn-like diagram to segment the market of RIA acquirors.Goldman Sachs | Investment Banking Pitch Book | 52 slides · Goldman Sachs
Consulting deck Investment bank Beat · Impact & Next StepsLoop · Cost Of Inaction1 hit
34
The chart highlights a clear valuation premium for RIA firms compared to IBD firms, with multiples trending upward over time.Goldman Sachs | Investment Banking Pitch Book | 52 slides · Goldman Sachs
Consulting deck Investment bank Beat · Impact & Next StepsLoop · Cost Of Inaction1 hit
35
Goldman Sachs | Investment Banking Pitch Book | 52 slidesGoldman Sachs | Investment Banking Pitch Book | 52 slides · Goldman Sachs
Consulting deck Investment bank Beat · Impact & Next StepsLoop · Cost Of Inaction1 hit
16
Includes a biological pathway diagram showing signaling cascades and a table of prevalence/incidence for three specific lymphoma types.Kymera | Results Presentation Deck | 63 slides · Kymera
Conference presentation Investor relations Beat · Solution1 hit
17
Shows efficacy data (tumor volume) alongside PK/PD mechanism data (degradation over time).Kymera | Results Presentation Deck | 63 slides · Kymera
Conference presentation Investor relations Beat · Solution1 hit
18
The slide uses a process flow diagram to illustrate dose escalation steps (0.16 to DLX) and a table for study objectives.Kymera | Results Presentation Deck | 63 slides · Kymera
Conference presentation Investor relations Beat · Solution1 hit
19
The slide highlights the absence of dose-limiting toxicities (DLTs) and serious adverse events (SAEs) in the initial dose cohorts.Kymera | Results Presentation Deck | 63 slides · Kymera
Conference presentation Investor relations Beat · Solution1 hit
20
The chart shows a log-scale y-axis for plasma concentration. The table summarizes Cmax, AUCinf, Vd, CL, and t1/2 for both dose levels.Kymera | Results Presentation Deck | 63 slides · Kymera
Conference presentation Investor relations Beat · Solution1 hit
21
The slide uses line charts for longitudinal PBMC data and a bar chart for tumor knockdown data, supported by summary tables.Kymera | Results Presentation Deck | 63 slides · Kymera
Conference presentation Investor relations Beat · Solution1 hit
22
POM = Proof of Mechanism; PK = Pharmacokinetics; PD = Pharmacodynamics; DL = Dose Level; KD = Knockdown; DLT = Dose-Limiting Toxicity; SAE = Serious Adverse Event.Kymera | Results Presentation Deck | 63 slides · Kymera
Conference presentation Investor relations Beat · Solution1 hit
23
Kymera | Results Presentation Deck | 63 slidesKymera | Results Presentation Deck | 63 slides · Kymera
Conference presentation Investor relations Beat · Solution1 hit
24
The slide uses a biological pathway diagram to contrast the 'scaffolding' and 'kinase' roles of IRAK4, arguing that degradation blocks both, whereas inhibitors only block the kinase role.Kymera | Results Presentation Deck | 63 slides · Kymera
Conference presentation Investor relations Beat · Solution1 hit